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dyslipidemia on the progression of renal insufficiency and dial-Ongoing clinical trials of lipid reduction therapy in patients
ysis-related cardiovascular complications.with renal disease.
Background. Lipid abnormalities in renal disease are associ-
ated with both a progressive decline in renal function and
cardiovascular complications. Whether or not lipid anomalies
Plasma lipoprotein metabolism is frequently abnormalare causal is not yet clear. Experimental studies have demon-
in renal disease. The principal clinical manifestationsstrated that potentially atherogenic lipoproteins, such as low
density lipoproteins (LDL), are associated with renal patho- of renal disease are proteinuria and progressive renal
physiological changes that result in progressive glomerular and failure, which ultimately requires dialysis or transplanta-
interstitial damage and an ultimate reduction in renal function. tion. These two conditions are associated with character-These findings indicate that hyperlipidemia accelerates glomer-
istic changes in the concentrations and composition ofular and interstitial damage in renal disease. Clinical studies
plasma lipoproteins.also show that renal function declines more rapidly among
patients with primary renal disease or diabetic nephropathy Our review briefly describes the effect of hypolip-
who have hyperlipidemia. However, few reports have demon- idemic agents on the progression of renal disease and
strated the effect of hypolipidemic agents on the progression
the cardiovascular complications of chronic renal failure.of renal function among patients with renal disease, and those
renal patients who were treated with lipid-lowering agents have
not been clinically studied under large-scale controlled condi-
POTENTIAL ROLE OF ABNORMALtions. In addition, although cardiovascular complications are
LIPOPROTEIN METABOLISM INthe most important factors associated with mortality in dialysis
patients, randomized, large-scale trials studying the relation- RENAL INJURY
ship between therapeutic intervention by lipid-lowering agents
The potential role of lipoprotein abnormalities in renaland prevention of cardiovascular complications have not been
injury is mainly based on experimental studies showingimplemented.
Methods. We reviewed controlled and uncontrolled re- an association between hyperlipidemia and degree of
ported studies that examined the effects of lipid-lowering ther- glomerular injury. In comparison, only a few studies sug-
apy in patients with renal disease.
gest a possible relationship between plasma lipoproteinResults. Most studies showed that 3-hydroxy-3-methylgluta-
anomalies and the rate of progression of human renalryl coenzyme A (HMG-CoA) reductase inhibitors reduce cho-
lesterol-rich apolipoprotein (apo)B-containing lipoproteins with disease [1]. According to a report describing nondiabetic
no effects on renal function or proteinuria among patients with patients with renal failure, renal function declines more
progressive renal disease. Small uncontrolled studies show that rapidly among those with hyperlipidemia than with nor-
simvastatin and probucol moderately reduce proteinuria among
molipidemia [2]. In addition, a subsequent study demon-patients with membranous nephropathy. One small retrospec-
strated a correlation between apolipoprotein (apo) A-1/Btive study showed that long-term vitamin E therapy reduces
aortic calcification in dialysis patients. ratio and the rate at which renal function decreases
Conclusions. Prospective, randomized large-scale trials in- among patients with renal insufficiency. In a retrospec-
cluding ongoing clinical trials of lipid reduction therapy and
tive study of patients with diabetic and nondiabetic renaltherapeutic interventions such as the use of the combination
disease, Samuelsson et al found a significant relationshiptherapy with hypolipidemic agents and angiotensin converting
enzyme (ACE) inhibitors, vitamins, or LDL apheresis are ur- between the rate of decline in renal function and in-
gently required. Such trials will clarify the effect of treating creased levels of plasma apo B and low density lipopro-
tein (LDL) cholesterol [3]. In a prospective study of 73
patients with primary renal disease in which decreasedKey words: hyperlipidemia, progressive renal disease, cardiovascular,
clinical trials, dialysis. renal function was significantly correlated with the base-
line levels of plasma cholesterol, LDL cholesterol and 1999 by the International Society of Nephrology
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apo B [4]. A more recent detailed lipoprotein analysis high density lipoprotein (HDL)-cholesterol (especially
HDL2) and probably a decrease in distribution of vita-of patients with chronic glomerulonephritis has demon-
min E in lipoproteins.strated that the characteristic abnormalities of triglycer-
In addition, cholesterol transport is often disturbed,ide-rich apoB-containing lipoproteins arising as a conse-
in that cholesterol transport from HDL to VLDL andquence of renal insufficiency may affect the progression
LDL is diminished, and reverse cholesterol transportof renal damage [5].
from peripheral tissues to the liver is inhibited. A de-
creased number of LDL receptors on the cell surface
EFFECT OF HYPOLIPIDEMIC AGENTS ON may also be associated with abnormal lipoprotein metab-
THE PROGRESSION OF RENAL DISEASE olism.
Lovastatin or simvastatin given to patients with ne- Qualitative lipoprotein abnormalities in uremic pa-
phrotic syndrome reduced cholesterol-rich apoB-con- tients such as oxidation (especially LDL), carbamylation
taining lipoproteins, but did not affect the progression and transformation by AGE have recently been demon-
of renal insufficiency or proteinuria [6]. On the other strated. Oxidized LDL may play an important role in
hand, among patients with membranous nephropathy, the formation of foam cells, which are associated with
simvastatin [7] or probucol [8, 9] moderately reduced atherosclerotic lesions in arterial walls. We showed that
proteinuria. plasma levels of LDL-malondialdehyde (MDA-LDL)
are significantly higher in dialysis patients than in normal
controls and that MDA-rich LDL is more rapidly takenPREVALENCE AND PROGRESSION OF
up by monocyte-scavenger receptors in vitro [11].ATHEROSCLEROSIS IN UREMIC PATIENTS
To date, a few studies have correlated lipid abnormali-
Atherosclerosis is frequently found in patients with ties with cardiovascular disease among dialysis patients.
end-stage renal disease. Cardio- or cerebrovascular Among patients with clinical evidence of vascular dis-
events are the most common causes of mortality among ease, plasma triglycerides were increased whereas HDL
such patients [10]. The reportedly high prevalence of cholesterol was low [12]. These factors may also play an
cardiovascular mortality in patients undergoing chronic important role in lipid disturbances such as atheroscle-
hemodialysis has been confirmed by numerous subse- rotic risk factors in the general population. However,
quent studies. A recent study by the ERA-EDTA Regis- the contribution of lipid abnormalities to accelerated
try demonstrated that the cardiovascular mortality rate atherosclerosis in dialysis patients remains controversial
among chronic dialysis patients was approximately 20- [10].
fold higher than that of the general population, and that
of the cerebrovascular death rate was about 10-fold
THERAPY OF DIALYSIS-RELATEDhigher. However, the question of whether or not athero-
LIPID ABNORMALITIES BYsclerosis among dialysis patients is accelerated remains
LIPID-LOWERING AGENTSunknown. It is thought that dialysis patients have vascu-
lar abnormalities before dialysis. Dialysis patients usu- Few reports describe the effect of hypolipidemic
ally have several coexistent risk factors, such as hyperten- agents on dialysis-related lipid abnormalities. Nishizawa
sion, dyslipidemia, glucose intolerance and cigarette et al found that clinofibrate reduced plasma levels of
smoking, all of which are additive. On the other hand, triglycerides and IDL, and increased HDL-cholesterol
such risk factors in the general population may be more concentrations [13]. In a recent prospective study of 38
often present as single risk factors. patients undergoing chronic hemodialysis therapy who
had high plasma cholesterol levels above 200 mg/dl or
low HDL cholesterol levels below 40 mg/dl, a 24 weekDISTURBANCES OF LIPID METABOLISM IN
treatment with simvastatin significantly reduced plasmaUREMIC PATIENTS
levels of cholesterol, apoB, apoE, Lp(a), MDA and
The most important lipid abnormalities in dialysis pa- apoB-containing lipoprotein (VLDL, IDL, LDL) choles-
tients are characterized as increased plasma levels of terol, but did not affect plasma triglyceride and HDL
triglycerides, very-low density lipoproteins (VLDL), in- cholesterol levels [14].
termediate density lipoproteins (IDL), cholesterol-rich
VLDL, lipoproteins containing apo B such as choles-
TREATMENT WITH HYPOLIPIDEMIC AGENTSterol-rich lipoprotein-B particles and triglyceride-rich
TO PREVENT ATHEROSCLEROSIS INcomplex lipoprotein-B particles, and lipoprotein(a) [Lp
DIALYSIS PATIENTS(a)]. Several qualitative lipoprotein changes are also
present, including lipoprotein oxidation, carbamylation, The relationship between the prevention of athero-
sclerosis and lipid-lowering medication in dialysis pa-advanced glycation end-products (AGE), a decrease in
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